Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...

Eli Lilly says it plans to submit orforglipron to the U.S. Food and Drug Administration ... further Lilly's mission to reduce chronic diseases like type 2 diabetes, which is expected to impact ...

Researchers have found that Sotyktu, which inhibits the protein TYK2, protects insulin-producing beta cells and, at the same ...

Eli Lilly Downplays CVS Move to Drop Zepbound Coverage, Shares Plunge By Bhanvi Satija and Patrick Wingrove (Reuters) -Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's ...

A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

Eli Lilly & Co.’s obesity drug ... reduce blood pressure and other metabolic parameters,” Aronne said. Patients lost an ...

Most notably, the bank downgraded Lilly to Reduce ... risk-reward for Eli Lilly (NYSE:LLY) is "not attractive," especially given uncertainties surrounding the future growth of its obesity drug ...